A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease

Journal of Negative Results in BioMedicine

Volumn 14, Issue 1, 2015, Pages

  Shafuddin, Eskandarain ^a   Mills, Graham D ^a   Holmes, Mark D ^b   Poole, Phillippa J ^c   Mullins, Peter R ^d   Black, Peter N ^c  

^a WAIKATO HOSPITAL   (New Zealand)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c THE UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PLACEBO; ROXITHROMYCIN;

ADULT; AGED; ARTICLE; CHLAMYDIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE COURSE; MIDDLE AGED; MULTICENTER STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AGED; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; ROXITHROMYCIN;

EID: 84940826112     PISSN: None     EISSN: 14775751     Source Type: Journal    
DOI: 10.1186/s12952-015-0034-8     Document Type: Article

References (29)

1. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis. 2009;4:245-51.
2. Staykova T, Black PN, Chacko EE, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003(1):CD004105 doi: 10.1002/14651858.CD004105 [published Online First: Epub Date].
3. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2013;11:CD009764. doi: 10.1002/14651858.CD009764. pub2[published Online First: Epub Date.
4. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361-8. doi: 10.1016/S2213-2600(14)70019-0. published Online First: Epub Date.
5. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98. doi: 10.1056/NEJMoa1104623. published Online First: Epub Date.
6. Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax. 2002;57(8):672-6.
7. Wu L, Skinner SJ, Lambie N, Vuletic JC, Blasi F, Black PN. Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1148-51. doi: 10.1164/ajrccm.162.3.9912134. published Online First: Epub Date.
8. Seemungal TA, Wedzicha JA, MacCallum PK, Johnston SL, Lambert PA. Chlamydia pneumoniae and COPD exacerbation. Thorax. 2002;57(12):1087-8. author reply 88-9.
9. Papaetis GS, Anastasakou E, Orphanidou D. Chlamydophila pneumoniae infection and COPD: more evidence for lack of evidence? Eur J Intern Med. 2009;20(6):579-85. doi: 10.1016/j.ejim.2009.05.006. published Online First: Epub Date.
10. Strachan DP, Carrington D, Mendall M, Butland BK, Yarnell JW, Elwood P. Chlamydia pneumoniae serology, lung function decline, and treatment for respiratory disease. Am J Respir Crit Care Med. 2000;161(2 Pt 1):493-7.
11. Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991;144(6):1408-10. doi: 10.1164/ajrccm/144.6.1408. published Online First: Epub Date.
12. Banerjee D, Honeybourne D, Khair OA. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med. 2004;3(1):59-65.
13. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther. 2010;23(3):200-7. doi: 10.1016/j.pupt.2009.12.002. published Online First: Epub Date.
14. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445-52. doi: 10.1159/000321374. published Online First: Epub Date.
15. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;17(11):1139-47. doi: 10.1164/rccm.200801-145OC. published Online First: Epub Date.
16. Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, et al. Erythromycin and common cold in COPD. Chest. 2001;120(3):730-3.
17. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respiratory research. 2010;11:10. doi: 10.1186/1465-9921-11-10. published Online First: Epub Date.
18. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst Rev. 2003(4):CD001392 doi: 10.1002/14651858.CD001392 [published Online First: Epub Date].
19. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother. 2004;54(1):21-8. doi: 10.1093/jac/dkh309. published Online First: Epub Date.
20. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251-9. doi: 10.1001/jama.2013.1937. published Online First: Epub Date.
21. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260-7. doi: 10.1001/jama.2013.2290. published Online First: Epub Date.
22. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660-7. doi: 10.1016/S0140-6736(12)60953-2. published Online First: Epub Date.
23. Brill SE, Law M, El-Emir E, Allinson JP, James P, Maddox V, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax. 2015. doi: 10.1136/thoraxjnl-2015-207194. published Online First: Epub Date.
24. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(3):331-50.
25. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-90. doi: 10.1056/NEJMoa1003833. published Online First: Epub Date.
26. Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992;14(1):178-82.
27. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992;36(7):1573-4.
28. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49(11):1215-9.
29. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-15.